SCHEMBL5136199

SCHEMBL5136199

CCCCn1c(CN(CCc2ccccc2OC)Cc2ccc3c(c2)OCO3)cnc1-c1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 11/20 0.47
HTR2B P41595 11/20 0.47
HTR2C P28335 10/20 0.47
TP53 P04637 4/20 0.46
C5AR1 P21730 1/20 0.46
POLB P06746 1/20 0.44
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
ADRB1 P08588 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
DRD2 P14416 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
DRD1 P21728 1/20 0.40
DRD4 P21917 1/20 0.40
SLC6A2 P23975 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137486 0.94 TP53 (0.52) HTR2AHTR2BHTR2CTP53C5AR1
SCHEMBL5137303 0.94 TP53 (0.51) HTR2AHTR2BHTR2CTP53C5AR1
SCHEMBL5136307 0.92 C5AR1 (0.46) HTR2AHTR2BHTR2CTP53C5AR1
SCHEMBL5135206 0.92 TP53 (0.45) HTR2AHTR2BHTR2CTP53C5AR1
SCHEMBL5136286 0.92 HTR2A (0.48) HTR2AHTR2BHTR2CTP53C5AR1
SCHEMBL5150126 0.92 C5AR1 (0.47) HTR2AHTR2BHTR2CTP53C5AR1
SCHEMBL5136215 0.91 HTR2A (0.57) HTR2AHTR2BHTR2CTP53SMN1; SMN2
SCHEMBL5135806 0.90 C5AR1 (0.46) HTR2AHTR2BHTR2CTP53C5AR1
SCHEMBL5136702 0.90 C5AR1 (0.51) HTR2AHTR2BHTR2CTP53C5AR1
SCHEMBL5136744 0.90 C5AR1 (0.47) HTR2AHTR2BHTR2CTP53C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed